课题基金 / 基金详情

Treatment of Preterm Birth with ProstaglandinF2alpha Receptor Modulators

Treatment of Preterm Birth with ProstaglandinF2alpha Receptor Modulators
前列腺素 F2α 受体调节剂治疗早产
批准号:
478447-2015
负责人:
Lubell, William
金额:
$10.44万
依托单位:
依托单位国家:
加拿大
项目类别:
Collaborative Health Research Projects
财政年份:
2015
资助国家:
加拿大
项目状态:
已结题
起止时间:
2015-01-01 至 2016-12-31

项目摘要

项目成果

Lubell, William的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Preterm birth (PTB) is the leading cause of newborn death and the second leading cause of child death. Children born preterm often have lifelong health issues, including cerebral palsy, cognitive impairement, blindness, deafness, respiratory illness and gastrointestinal disorders, as well as chronic diseases such as hypertension and dyslipidemia. Hospital costs associated with PTB are among the most expensive: premature babies remain hospitalized an average of 11 days longer at a higher cost compared to term births; newborns born prior to 28 weeks gestation incur major costs (~$100,000/infant). In spite of a better understanding of risk factors and mechanisms related to premature contractions, and the introduction of public health prevention programs, the rate of PTB has increased. The economic implications of PTB make it the most costly medical urgency per patient. These statistics demonstrate that significant savings could be obtained by the development of effective treatments, which can prolong gestation, so called tocolytic agents. Prostaglandin-F2alpha (PGF2alpha) initiates labour, induces childbirth, and works in compliment with the small peptide hormone oxytocin, which is commonly used to induce labor in humans. Towards the development of a new tocolytic agent, we targeted the PGF2alpha receptor (FP) for two specific reasons: 1) FP expression increases during the initial phase of parturition, and 2) FP ''knock-out'' mice do not go into labour and must be delivered by cesarian. By creating a series of novel modulators, including peptide-based analogs proving successful in clinical studies, we have validated FP as a viable target. The proposed research is designed to further develop our prototypes to provide basic knowledge of the role of FP in parturition, to train highly qualified personnel in interdisciplinary research, and to develop effective therapy to treat preterm labour (PTL) to enhance quality of life from birth which impacts throughout life.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advances in Amino Acid Chemistry and Peptide Mimicry
  • 批准号:
    RGPIN-2019-04079
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $5.76万
  • 财政年份:
    2022
  • 负责人:
    Lubell, William
  • 依托单位:
Advances in Amino Acid Chemistry and Peptide Mimicry
  • 批准号:
    RGPIN-2019-04079
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $5.76万
  • 财政年份:
    2021
  • 负责人:
    Lubell, William
  • 依托单位:
Azacyclopeptide Modulators of Immuno-metabolism to Treat Age-Related Macular Degeneration
  • 批准号:
    538816-2019
  • 项目类别:
    Collaborative Health Research Projects
  • 资助金额:
    $20.77万
  • 财政年份:
    2020
  • 负责人:
    Lubell, William
  • 依托单位:
Advances in Amino Acid Chemistry and Peptide Mimicry
  • 批准号:
    RGPIN-2019-04079
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $5.76万
  • 财政年份:
    2020
  • 负责人:
    Lubell, William
  • 依托单位:
海外基金